Diabetic macular edema (DME) is the accumulation of fluid in the macula due to leaking blood vessels resulting from diabetic retinopathy. Therapies targeting vascular endothelial growth factor (VEGF) have been shown to improve visual acuity in DME patients. The anti-VEGF agents used in the treatment of DME are Lucentis and Eylea—both approved for the treatment of DME—and off-label Avastin. In addition to the anti-VEGF therapies, two long-acting intravitreal corticosteroid implants, Ozurdex and Iluvien, were approved in the United States in 2014 for the treatment of DME. Given the competitive DME market, it is essential to understand how DME patients are currently being treated using real-world data.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed DME patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DME patients?
- How have intravitreal corticosteroid implants been integrated into the treatment algorithm?
- What proportion of DME patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of DME patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with DME?
Real World Data
Longitudinal patient-level claims data analysis
Key Drugs Covered
Avastin, Eylea, Iluvien, Lucentis, Ozurdex, triamcinolone
Key Analysis Provided
- Brand/Therapy Usage Across Longitudinal Patient Sample
- Newly Diagnosed Patient Analysis
- Treatment Initiation and Progression Line of Therapy Analysis
- Combination Therapy Analysis
- Source of Business for Recently Treated Patients
- Persistency and Compliance Analysis
- Product-level Patient Flow Charts
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.
- Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- 2019 Treatment Algorithms: Claims Data Analysis in Diabetic Macular Edema (January 2019)
Author(s): Natalie Taylor, PhD
Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.